Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells
November 19th, 2020
6.3K views
This protocol details an adapted method to derive, expand, and cryopreserve brain microvascular endothelial cells obtained by differentiating human induced pluripotent stem cells, and to study blood brain barrier properties in an ex vivo model.
Overview
This study presents a protocol for differentiating, expanding, and cryopreserving brain microvascular endothelial cells (BMECs) from human induced pluripotent stem cells (iPSCs). It focuses on investigating blood-brain barrier properties using an ex vivo model.
Key Study Components
Area of Science
- Neuroscience
- Stem Cell Biology
- Vascular Biology
Background
- BMECs play a crucial role in maintaining blood-brain barrier integrity.
- Disruptions in the blood-brain barrier are implicated in various neurological disorders.
- Human iPSCs provide a model for personalized medicine approaches.
- The protocol allows the generation of disease-specific BMECs.
Purpose of Study
- To optimize the differentiation protocol for BMECs derived from iPSCs.
- To evaluate the effects of expansion and cryopreservation on barrier properties.
- To investigate the applicability of these BMECs in studying blood-brain barrier function.
Methods Used
- The method relies on differentiation of human iPSCs into BMECs via a stepwise cell culture protocol.
- Key steps include culturing in specific media, the use of ROCK inhibitors, and transwell assays for barrier property assessment.
- TEER measurements and efflux transporter assays are used for functional analysis.
- Cell morphology and differentiation efficiency are monitored over eight days.
Main Results
- BME cells maintained tight junction properties and appropriate morphology post-differentiation.
- TEER values indicated functional integrity; however, cryopreservation reduced these properties.
- Efflux transporter activity was demonstrated, suggesting preserved functionality.
- The methodology allows for the modeling of blood-brain barrier mechanisms in health and disease.
Conclusions
- This protocol enables the generation of patient-derived BMECs for studying blood-brain barrier function.
- It provides insights into the effects of cryopreservation on barrier properties.
- The study has implications for developing therapeutic strategies targeting the blood-brain barrier.
Frequently Asked Questions
What are the advantages of using iPSC-derived BMECs?
iPSC-derived BMECs offer a patient-specific model that accurately represents individual blood-brain barrier conditions and dysfunctions.
How is the differentiation of iPSCs into BMECs achieved?
The differentiation involves culturing iPSCs in enzymatic EDTA, followed by exposure to a specific growth factor medium and coatings to promote endothelial characteristics.
What types of data are obtained from this model?
Functional data such as TEER measurements and efflux transporter activity, alongside morphological assessments and expression of tight junction proteins, are obtained.
How can this method be adapted for different research needs?
The protocol can be customized to model specific diseases by utilizing patient-derived iPSCs and modifying growth conditions to reflect disease mechanisms.
What are the limitations of the model?
Variability in differentiation efficiency and the impact of cryopreservation on cell functionality may affect reproducibility and experimental outcomes.
Executive Industry Relevance
Human iPSC-derived brain microvascular endothelial cells (BMECs) enable the development of ex vivo blood-brain barrier (BBB) models for early-stage CNS drug discovery and mechanistic de-risking. This protocol supports the generation, expansion, and cryopreservation of BMECs, facilitating disease-relevant system modeling and functional validation of BBB properties. The approach enhances predictive confidence for BBB permeability and transporter function, directly impacting portfolio triage and translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of BBB integrity and transporter activity in disease-relevant human systems.
- Supports mechanistic de-risking by modeling patient-specific BBB dysfunction.
- Facilitates functional target validation for CNS drug delivery strategies.
- Provides a platform for hypothesis testing of BBB-related therapeutic mechanisms.
Screening & Assay Development
- Delivers standardized BMEC monolayers for quantitative TEER and efflux transporter assays.
- Enables reproducible assessment of compound permeability across the BBB.
- Supports assay scalability and platform reuse for high-content screening.
- Prepares validated biological systems for downstream co-culture and organoid workflows.
Translational & Preclinical Research
- Aligns in vitro BBB models with translational biomarker endpoints such as TEER and transporter activity.
- Provides continuity from discovery through preclinical validation of CNS drug candidates.
- Enables risk-adjusted advancement decisions based on human-relevant BBB function.
- Supports modeling of BBB dysfunction in neuropsychiatric and neurodegenerative disorders.
Pipeline & Workflow Integration
This protocol positions iPSC-derived BMECs as a bridge from early discovery to preclinical CNS drug evaluation, supporting both target validation and lead identification.
- Discovery Biology: Enables hypothesis testing of BBB mechanisms and pathway clarification in human-derived systems.
- Screening: Provides reproducible, quantitative TEER and transporter activity readouts for compound evaluation.
- Analytics: Delivers standardized measurements for cross-condition comparison and statistical analysis.
- Translational Research: Facilitates alignment with preclinical BBB biomarkers and disease modeling.
- Enterprise Reuse: Establishes a reusable platform for diverse CNS drug discovery and disease modeling initiatives.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in BBB permeability and transporter function for CNS portfolios.
- Operational Value: Standardizes BMEC derivation, expansion, and cryopreservation for reproducible workflows.
- Strategic Value: Improves go/no-go decisions by providing human-relevant BBB data early in the pipeline.
- Portfolio Impact: Enables risk-adjusted prioritization of CNS assets based on functional BBB validation.
Implementation Considerations
- Requires expertise in iPSC culture, differentiation, and endothelial cell biology.
- Needs access to TEER instrumentation, multi-plate readers, and immunocytochemistry infrastructure.
- Demands cross-team standardization of cell density, media, and matrix coatings for reproducibility.
- Adaptation across disease models may require protocol optimization for specific iPSC lines.
- Lower TEER and marker localization after cryopreservation may limit some downstream applications.
Biopharma FAQs
Why does null hypothesis testing of TEER measurements matter for target validation?
Null hypothesis testing of TEER values enables objective assessment of BBB integrity, supporting functional target validation and reducing mechanistic ambiguity in CNS drug discovery.
How does independent variable isolation in efflux transporter assays fit the discovery pipeline?
Isolating variables in efflux transporter assays allows teams to attribute changes in substrate transport to specific interventions, strengthening mechanistic insights and informing lead optimization.
What do quantitative dependent variable measurements like TEER and transporter activity enable?
Quantitative TEER and transporter activity measurements provide standardized, reproducible outputs for comparing BBB function across conditions, supporting data-driven advancement decisions.
Why are replication requirements for BMEC differentiation and TEER analysis critical for cross-functional collaboration?
Replication ensures that BMEC differentiation and TEER results are robust and transferable, enabling reliable data sharing and decision-making across discovery, screening, and translational teams.
What statistical analysis capabilities are required before implementing BMEC-based BBB models?
Teams must establish statistical methods for analyzing TEER, transporter activity, and marker expression data to ensure rigorous interpretation and portfolio-relevant conclusions.
Chapters in this video
0:04
Introduction
0:38
Brain Microvascular Endothelial Cell (BMEC) Differentiation from Human Induced Pluripotent Stem Cell (iPSC)
1:46
iPSC-Derived BMEC Subculture and Purification
3:02
Trans-Endothelial Electrical Resistance (TEER) Measurement and Analysis
4:09
Efflux Transporter Activity and Analysis
5:22
Results: Representative BMEC Differentiation and Characterization After Passaging, Subculture, and Cryopreservation
7:18
Conclusion
